Based on data from MarketBeat, Vaxcyte presently has a consensus rating of “Hold” and an average price target of $86.00. Vaxcyte consensus rating reportBrokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Also, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction dated Monday, August 3rd. Institutional Inflows and OutflowsA number of hedge funds have recently bought and sold shares of the business.